Recruiting

Molecular & Genetic Analysis

Sponsor:

Massachusetts General Hospital

Code:

NCT03029325

Conditions

Lung Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Study Details

Brief summary:

Investigators use a genome-wide approach within a case-control design to identify SNPs that show evidence of association with lung cancer risk and survival.

Conditions

Lung Cancer

Study ID

NCT03029325

Start date

Jun, 1993

Status verified date

Nov, 2024

Completion date

Sep, 2026

Anticipated

Primary completion date

Sep, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • healthy controls: participants without evidence of any cancer
  • cases: pathology proven primary lung cancer

Exclusion Criteria:

  • younger than 18 years old

Study Design

Enrollment

15000 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

  • Survival among patients at different stages of lung cancer and treatment will be measured using questionnaires along with medical chart data to monitor treatment and disease progression [ Time Frame: 20 years ]

Central Contacts and Locations

Central contacts

David Christiani, MD

617-726-9274dchris@hsph.harvard.edu

Andrea Shafer, MPH

6177269274ashafer@mgh.harvard.edu

Locations

Massachusetts General Hospital

Recruiting

Boston, Massachusetts, United States, 02114

Contacts

Andrea Shafer, MPH

6177269274

More Information

Sponsor

Massachusetts General Hospital

Last update posted

Nov 29, 2024

Last verified

Nov, 2024

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Massachusetts General Hospital on 2024-11-29.